Mainz Biomed to Present at the H.C. Wainwright Bioconnect Virtual Conference

BERKELEY, US – MAINZ, Germany – JANUARY 11th, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, will present at the H.C. Wainwright Bioconnect Virtual Conference taking place on January 10-13, 2022. To […]